AAAAAA

   
Results: 1-25 | 26-30
Results: 1-25/30
OUTPATIENT TOLERABILITY OF HIGH-DOSE LIPOSOME-ENCAPSULATED DAUNORUBICIN (DAUNOXOME(R)) WITH FILGRASTIM SUPPORT IN PATIENTS WITH SOLID TUMORS
Authors: DEMETRI GD GEIGER EA XU G STEFANOWICZ L JOYCE R RICHARDSON P ELIAS AD
Citation: Gd. Demetri et al., OUTPATIENT TOLERABILITY OF HIGH-DOSE LIPOSOME-ENCAPSULATED DAUNORUBICIN (DAUNOXOME(R)) WITH FILGRASTIM SUPPORT IN PATIENTS WITH SOLID TUMORS, Annals of oncology, 9, 1998, pp. 490-490
TROGLITAZONE INDUCES DIFFERENTIATION AND DECREASES PROLIFERATION OF LIPOSARCOMA IN PHASE-II TRIAL
Authors: DEMETRI GD FLETCHER CD SPIEGELMAN B GEIGER E SINGER S
Citation: Gd. Demetri et al., TROGLITAZONE INDUCES DIFFERENTIATION AND DECREASES PROLIFERATION OF LIPOSARCOMA IN PHASE-II TRIAL, Annals of oncology, 9, 1998, pp. 669-669
NCCN SARCOMA PRACTICE GUIDELINES
Authors: DEMETRI GD POLLOCK R BAKER L BALCERZAK S CASPER E CONRAD C FEIN D HUTCHINSON R SCHUPAK K SPIRO I WAGMAN L
Citation: Gd. Demetri et al., NCCN SARCOMA PRACTICE GUIDELINES, Oncology, 12(7A), 1998, pp. 183-218
QUALITY-OF-LIFE BENEFIT IN CHEMOTHERAPY PATIENTS TREATED WITH EPOETIN-ALPHA IS INDEPENDENT OF DISEASE RESPONSE OR TUMOR TYPE - RESULTS FROMA PROSPECTIVE COMMUNITY ONCOLOGY STUDY
Authors: DEMETRI GD KRIS M WADE J DEGOS L CELLA D
Citation: Gd. Demetri et al., QUALITY-OF-LIFE BENEFIT IN CHEMOTHERAPY PATIENTS TREATED WITH EPOETIN-ALPHA IS INDEPENDENT OF DISEASE RESPONSE OR TUMOR TYPE - RESULTS FROMA PROSPECTIVE COMMUNITY ONCOLOGY STUDY, Journal of clinical oncology, 16(10), 1998, pp. 3412-3425
HEMATOLOGICAL AND QUALITY-OF-LIFE (QOL) OUTCOMES IN ANEMIC CANCER-PATIENTS TREATED, WITH EPOETIN-ALPHA
Authors: GLASPY J DEMETRI GD
Citation: J. Glaspy et Gd. Demetri, HEMATOLOGICAL AND QUALITY-OF-LIFE (QOL) OUTCOMES IN ANEMIC CANCER-PATIENTS TREATED, WITH EPOETIN-ALPHA, British Journal of Haematology, 102(1), 1998, pp. 336-336
DETECTION OF CIRCULATING TUMOR-CELLS IN PATIENTS WITH EWINGS-SARCOMA AND PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Authors: WEST DC GRIER HE SWALLOW MM DEMETRI GD GRANOWETTER L SKLAR J
Citation: Dc. West et al., DETECTION OF CIRCULATING TUMOR-CELLS IN PATIENTS WITH EWINGS-SARCOMA AND PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR, Journal of clinical oncology, 15(2), 1997, pp. 583-588
DOSE INTENSIFICATION OF LIPOSOME-ENCAPSULATED DAUNORUBICIN (DAUNOXOME(R)) WITH FILGRASTIM SUPPORT IN PATIENTS (PTS) WITH SOLID TUMORS
Authors: DEMETRI GD STEFANOWICZ L GEIGER EA XU G RICHARDSON P ELIAS AD
Citation: Gd. Demetri et al., DOSE INTENSIFICATION OF LIPOSOME-ENCAPSULATED DAUNORUBICIN (DAUNOXOME(R)) WITH FILGRASTIM SUPPORT IN PATIENTS (PTS) WITH SOLID TUMORS, Blood, 90(10), 1997, pp. 4357-4357
THE INCIDENCE OF THROMBOTIC AND EMBOLIC EVENTS IN CONTROLLED CLINICAL-TRIALS OF BREAST-CANCER (CA) PATIENTS (PTS) UNDERGOING HIGH-DOSE CHEMOTHERAPY (HDC) WITH THE STAMP-I REGIMEN AND AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) TRANSPLANTATION
Authors: VREDENBURGH J GLASPY J BOLWELL B DEMETRI GD KIN B JELACAMAXWELL K SHPALL EJ
Citation: J. Vredenburgh et al., THE INCIDENCE OF THROMBOTIC AND EMBOLIC EVENTS IN CONTROLLED CLINICAL-TRIALS OF BREAST-CANCER (CA) PATIENTS (PTS) UNDERGOING HIGH-DOSE CHEMOTHERAPY (HDC) WITH THE STAMP-I REGIMEN AND AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) TRANSPLANTATION, Blood, 90(10), 1997, pp. 972-972
EFFECTS OF PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR (PEG-RHUMGDF) BEFORE HIGH-DOSE CHEMOTHERAPY (HDC) WITH PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) SUPPORT
Authors: GLASPY J VREDENBURGH J DEMETRI GD CHAP L GILBERT C OVERMOYER B WARREN DL BERG R SCARLATA D MENCHACA D BOLWELL B
Citation: J. Glaspy et al., EFFECTS OF PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR (PEG-RHUMGDF) BEFORE HIGH-DOSE CHEMOTHERAPY (HDC) WITH PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) SUPPORT, Blood, 90(10), 1997, pp. 2582-2582
CHEMOTHERAPY AND NEUTROPENIA
Authors: KIM SK DEMETRI GD
Citation: Sk. Kim et Gd. Demetri, CHEMOTHERAPY AND NEUTROPENIA, Hematology/oncology clinics of North America, 10(2), 1996, pp. 377
SYNOVIAL SARCOMA - PROGNOSTIC-SIGNIFICANCE OF TUMOR SIZE, MARGIN OF RESECTION, AND MITOTIC-ACTIVITY FOR SURVIVAL
Authors: SINGER S BALDINI EH DEMETRI GD FLETCHER JA CORSON JM
Citation: S. Singer et al., SYNOVIAL SARCOMA - PROGNOSTIC-SIGNIFICANCE OF TUMOR SIZE, MARGIN OF RESECTION, AND MITOTIC-ACTIVITY FOR SURVIVAL, Journal of clinical oncology, 14(4), 1996, pp. 1201-1208
THE EMERGENCE OF PERIPHERAL-BLOOD PROGENITOR CELLS TO SUPPORT INTENSIVE CHEMOTHERAPY FOR PATIENTS WITH BREAST-CANCER
Authors: DEMETRI GD
Citation: Gd. Demetri, THE EMERGENCE OF PERIPHERAL-BLOOD PROGENITOR CELLS TO SUPPORT INTENSIVE CHEMOTHERAPY FOR PATIENTS WITH BREAST-CANCER, Pharmacotherapy, 16(3), 1996, pp. 94-100
HIGH-DOSE IFOSFAMIDE IN THE TREATMENT OF SARCOMAS OF TISSUES AND BONE
Authors: DEMETRI GD
Citation: Gd. Demetri, HIGH-DOSE IFOSFAMIDE IN THE TREATMENT OF SARCOMAS OF TISSUES AND BONE, Seminars in oncology, 23(3), 1996, pp. 22-26
DOSE SCHEDULING OF IFOSFAMIDE - DISCUSSION
Authors: MARKMAN M GOREN MP DEMETRI GD THIGPEN T NICHOLS CR ETTINGER DS CHANG AY VOSE JM OVERMOYER BA PRATT CB ROTH BJ PALACKDHARRY CS
Citation: M. Markman et al., DOSE SCHEDULING OF IFOSFAMIDE - DISCUSSION, Seminars in oncology, 23(3), 1996, pp. 99-102
NEUROTOXICITY OF IFOSFAMIDE THERAPY - DISCUSSION
Authors: MARKMAN M ETTINGER DS THIGPEN T NICHOLS CR CHANG AY DEMETRI GD VOSE JM PALACKDHARRY CS
Citation: M. Markman et al., NEUROTOXICITY OF IFOSFAMIDE THERAPY - DISCUSSION, Seminars in oncology, 23(3), 1996, pp. 103-104
KINETICS OF PERIPHERAL-BLOOD MONONUCLEAR CELL MOBILIZATION WITH CHEMOTHERAPY AND OR GRANULOCYTE-COLONY-STIMULATING FACTOR - IMPLICATIONS FOR TIMING AND YIELD OF HEMATOPOIETIC PROGENITOR-CELL COLLECTIONS/
Authors: WEBB IJ EICKHOFF CE ELIAS AD AYASH LJ WHEELER CA SCHWARTZ GN DEMETRI GD ANDERSON KC
Citation: Ij. Webb et al., KINETICS OF PERIPHERAL-BLOOD MONONUCLEAR CELL MOBILIZATION WITH CHEMOTHERAPY AND OR GRANULOCYTE-COLONY-STIMULATING FACTOR - IMPLICATIONS FOR TIMING AND YIELD OF HEMATOPOIETIC PROGENITOR-CELL COLLECTIONS/, Transfusion, 36(2), 1996, pp. 160-167
RECOMBINANT HUMAN STEM-CELL FACTOR (KIT-LIGAND) PROMOTES HUMAN MAST-CELL AND MELANOCYTE HYPERPLASIA AND FUNCTIONAL ACTIVATION IN-VIVO
Authors: COSTA JJ DEMETRI GD HARRIST TJ DVORAK AM HAYES DF MERICA EA MENCHACA DM GRINGERI AJ SCHWARTZ LB GALLI SJ
Citation: Jj. Costa et al., RECOMBINANT HUMAN STEM-CELL FACTOR (KIT-LIGAND) PROMOTES HUMAN MAST-CELL AND MELANOCYTE HYPERPLASIA AND FUNCTIONAL ACTIVATION IN-VIVO, The Journal of experimental medicine, 183(6), 1996, pp. 2681-2686
RESULTS OF SINGLE-AGENT AND COMBINATION CHEMOTHERAPY FOR ADVANCED SOFT-TISSUE SARCOMAS - IMPLICATIONS FOR DECISION-MAKING IN THE CLINIC
Authors: DEMETRI GD ELIAS AD
Citation: Gd. Demetri et Ad. Elias, RESULTS OF SINGLE-AGENT AND COMBINATION CHEMOTHERAPY FOR ADVANCED SOFT-TISSUE SARCOMAS - IMPLICATIONS FOR DECISION-MAKING IN THE CLINIC, Hematology/oncology clinics of North America, 9(4), 1995, pp. 765-785
RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ASAN ADJUNCT TO CONVENTIONAL-DOSE IFOSFAMIDE-BASED CHEMOTHERAPY FOR PATIENTS WITH ADVANCED OR RELAPSED GERM-CELL TUMORS - A RANDOMIZED TRIAL
Authors: BAJORIN DF NICHOLS CR SCHMOLL HJ KANTOFF PW BOKEMEYER C DEMETRI GD EINHORN LH BOSL GJ
Citation: Df. Bajorin et al., RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ASAN ADJUNCT TO CONVENTIONAL-DOSE IFOSFAMIDE-BASED CHEMOTHERAPY FOR PATIENTS WITH ADVANCED OR RELAPSED GERM-CELL TUMORS - A RANDOMIZED TRIAL, Journal of clinical oncology, 13(1), 1995, pp. 79-86
RECOMBINANT HUMAN STEM-CELL FACTOR (SCF) (C-KIT LIGAND) PROMOTES MELANOCYTE HYPERPLASIA AND ACTIVATION IN-VIVO
Authors: HARRIST TJ COSTA JJ DEMETRI GD DVORAK AM HAYES DF MERICA EA MENCHACA D GRINGERI AJ GALLI SJ
Citation: Tj. Harrist et al., RECOMBINANT HUMAN STEM-CELL FACTOR (SCF) (C-KIT LIGAND) PROMOTES MELANOCYTE HYPERPLASIA AND ACTIVATION IN-VIVO, Laboratory investigation, 72(1), 1995, pp. 48-48
HEMATOPOIETIC GROWTH-FACTORS - DEFINING THE APPROPRIATE CLINICAL ROLEIN MULTIMODALITY CANCER-THERAPY
Authors: DEMETRI GD
Citation: Gd. Demetri, HEMATOPOIETIC GROWTH-FACTORS - DEFINING THE APPROPRIATE CLINICAL ROLEIN MULTIMODALITY CANCER-THERAPY, Chest, 107(6), 1995, pp. 255-260
PROGNOSTIC FACTORS PREDICTIVE OF SURVIVAL FOR TRUNCAL AND RETROPERITONEAL SOFT-TISSUE SARCOMA
Authors: SINGER S CORSON JM DEMETRI GD HEALEY EA MARCUS K EBERLEIN TJ
Citation: S. Singer et al., PROGNOSTIC FACTORS PREDICTIVE OF SURVIVAL FOR TRUNCAL AND RETROPERITONEAL SOFT-TISSUE SARCOMA, Annals of surgery, 221(2), 1995, pp. 185-195
THE USE OF HEMATOPOIETIC GROWTH-FACTORS TO SUPPORT CYTOTOXIC CHEMOTHERAPY FOR PATIENTS WITH BREAST-CANCER
Authors: DEMETRI GD
Citation: Gd. Demetri, THE USE OF HEMATOPOIETIC GROWTH-FACTORS TO SUPPORT CYTOTOXIC CHEMOTHERAPY FOR PATIENTS WITH BREAST-CANCER, Hematology/oncology clinics of North America, 8(1), 1994, pp. 233-249
RECOMBINANT HUMAN STEM-CELL FACTOR (RHSCF) INDUCES CUTANEOUS MAST-CELL ACTIVATION AND HYPERPLASIA, AND HYPERPIGMENTATION IN HUMANS IN-VIVO
Authors: COSTA JJ DEMETRI GD HARRIST TJ DVORAK AM HAYES DF MERICA EA MENCHACA DM GRINGERI AJ GALLI SJ
Citation: Jj. Costa et al., RECOMBINANT HUMAN STEM-CELL FACTOR (RHSCF) INDUCES CUTANEOUS MAST-CELL ACTIVATION AND HYPERPLASIA, AND HYPERPIGMENTATION IN HUMANS IN-VIVO, Journal of allergy and clinical immunology, 93(1), 1994, pp. 225-225
CHANGES IN TC-99M RADIONUCLIDE BONE-SCAN IMAGES AND PERIPHERALIZATIONOF MARROW HEMATOPOIETIC ACTIVITY ASSOCIATED WITH THE ADMINISTRATION OF GRANULOCYTE-COLONY-STIMULATING FACTOR AS AN ADJUNCT TO DOSE-INTENSIFIED CHEMOTHERAPY FOR BREAST-CANCER - A CASE-REPORT
Authors: SALGIA R DEMETRI GD KAPLAN WD
Citation: R. Salgia et al., CHANGES IN TC-99M RADIONUCLIDE BONE-SCAN IMAGES AND PERIPHERALIZATIONOF MARROW HEMATOPOIETIC ACTIVITY ASSOCIATED WITH THE ADMINISTRATION OF GRANULOCYTE-COLONY-STIMULATING FACTOR AS AN ADJUNCT TO DOSE-INTENSIFIED CHEMOTHERAPY FOR BREAST-CANCER - A CASE-REPORT, Cancer, 74(7), 1994, pp. 1887-1890
Risultati: 1-25 | 26-30